| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Nicodicosapent does not interact with the GPR109A receptor, however it does decrease the mature SREBP-2 protein synthesis in HepG2 cells. With an IC50 value of 17 μM, nicodicosapent demonstrated synergistic inhibition of secreted PCSK9. With an IC50 of 27 μM, nicodicosapent substantially and dose-dependently suppresses ApoB secretion. In HepG2 cells, nicosapent induces hydrolysis in a time-dependent manner [1].
|
|---|---|
| ln Vivo |
Nicotinic acid is produced in large amounts in plasma by nicodicosapent (100 mg/kg po). Treatment with Nicodicosapent significantly decreased the levels of PCSK9, LDL particles (including VLDL and LDL cholesterol), and plasma triglycerides in ApoE*3-Leiden mice [1].
|
| References |
| Exact Mass |
449.304
|
|---|---|
| CAS # |
1269181-69-2
|
| PubChem CID |
50991753
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
677.5±55.0 °C at 760 mmHg
|
| Flash Point |
363.5±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
5.65
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
33
|
| Complexity |
662
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCNC(=O)C1=CN=CC=C1
|
| InChi Key |
YYQALOWPCKMFDQ-JLNKQSITSA-N
|
| InChi Code |
InChI=1S/C28H39N3O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-21-27(32)30-23-24-31-28(33)26-20-19-22-29-25-26/h3-4,6-7,9-10,12-13,15-16,19-20,22,25H,2,5,8,11,14,17-18,21,23-24H2,1H3,(H,30,32)(H,31,33)/b4-3-,7-6-,10-9-,13-12-,16-15-
|
| Chemical Name |
N-[2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]ethyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~222.41 mM)
Ethanol : ~3.33 mg/mL (~7.41 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (8.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
